由1个或2个植入物支持的下外的有效性:总体系统性审查
Journal of the American Dental Association (1939)
|September 4, 2025
概括
单个植入物保持下牙 (1i-MO) 在植入物损失和假肢失效方面显示短期益处. 然而,长期有效性和以患者为中心的结果仍然不确定,需要进一步研究.
科学领域:
- 牙科植入物学
- 牙整形
- 系统审查方法
背景情况:
- 评估下牙的现有系统审查的方法质量.
- 将单个植入式下牙 (1i-MO) 与两个植入式下牙 (2i-MO) 进行比较.
研究的目的:
- 评估1i-MO与2i-MO的临床和以患者为中心的有效性.
- 评估所包含的系统审查的方法质量.
主要方法:
- 对现有系统审查进行总体系统审查 (包括或不包括元分析).
- 在主要数据库 (PubMed,Scopus,Embase等) 进行文献搜索 直到2024年6月.
- 使用系统审查中的偏差风险工具评估偏差风险.
主要成果:
- 八项系统性审查符合纳入标准;偏差风险低于62. 5%和高于37. 5%.
- 短期证据支持1i-MO用于植入物损失,假肢失败和边际骨损失.
- 长期有效性和以患者为中心的结局 (满意度,生活质量) 由于结果不显著且置信区间很宽,因此无法确定.
结论:
- 虽然1i-MOs可能提供短期优势,但1i-MOs和2i-MOs之间的临床意义上的差异并未始终被证明.
- 患者为中心的不确定的结果和一些审查中的重大偏见风险凸显了进一步高质量的研究的必要性.
- 目前的证据并不能强烈地支持一个超额形结构的长期下稳定性和患者的福祉.
更多相关视频
05:54Real-Time Dynamic Navigation System for the Precise Quad-Zygomatic Implant Placement in a Patient with a Severely Atrophic Maxilla
Published on: October 18, 2021
1.9K
06:36Effects of Mechanical Methods Used in Peri-implantitis Treatment on Implant Surface Decontamination and Roughness
Published on: March 14, 2025
358
相关概念视频
Bioavailability Study Design: Single Versus Multiple Dose Studies
388
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
388
Bioequivalence of Drugs: Drugs with Multiple Indications
230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230
